Non-invasive systems and methods for selective activation of photoreactive responses

Patent metadata

Field	Value
Publication number	US-2017239489-A1
Application number	US-201515504917-A
Country	US
Kind code	A1
Filing date	Aug 17, 2015
Priority date	Aug 18, 2014
Publication date	Aug 24, 2017
Grant date	—

Abstract

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

First claim

1 . A method for affecting a predetermined change in biological activity to a target structure, comprising:
providing in a vicinity of or within the target structure one or more light emitters capable of emitting at least two different wavelengths of light, each wavelength of light associated with a different biological response; applying initiation energy from at least one source to the target structure, activating plural biological responses in the target structure depending on the different wavelengths of light provided internally within the target structure, wherein the different wavelengths activate different biological responses.

2 . The method of claim 1 , wherein the initiation energy contacts the target structure, activates the one or more biological responses, and induces the predetermined change in the target structure.

3 . The method of claim 1 , wherein activating plural biological responses comprises activating a first biological response with a first wavelength of light and a second biological response with a second wavelength of light.

4 . The method of claim 3 , wherein activating a first biological response comprises activating psoralen.

5 . The method of claim 4 , wherein activating a second biological response comprises generating a reactive oxygen species.

6 . The method of claim 3 , wherein activating a first biological response comprises at least one of photoactivating a drug, sterilizing the target structure, photoactivating psoralen, generating a reactive oxygen species, inducing an autoimmune response, exciting a DNA strand of a cancer cell, redirecting a metabolic pathway, up-regulating genes, down-regulating genes, secreting cytokines, altering cytokine receptor responses, releasing metabolites, or combinations thereof.

7 . The method of claim 3 , wherein activating a second biological response comprises at least one of photoactivating a drug, sterilizing the target structure, photoactivating psoralen, generating a reactive oxygen species, inducing an autoimmune response, exciting a DNA strand of a cancer cell, redirecting a metabolic pathway, up-regulating genes, down-regulating genes, secreting cytokines, altering cytokine receptor responses, releasing metabolites, or combinations thereof.

8 . The method of claim 3 , wherein activating a first biological response comprises bonding a pharmaceutical agent to a cellular structure.

9 . The method of claim 8 , wherein the bonding comprises bonding the pharmaceutical agent to at least one of nuclear DNA, mRNA, rRNA, ribosome, or mitochondrial DNA.

10 . The method of claim 3 , wherein at least one of said activating a first biological response and said activating a second biological response comprises altering a cellular response or a metabolic rate of the target structure.

11 . The method of claim 3 , wherein activating a first biological response comprises emitting ultraviolet light to act as a germicide, and wherein activating a second biological response comprises emitting near infrared light to act as an anti-inflammatory.

12 . The method of claim 3 , wherein activating a first biological response comprises emitting ultraviolet light to act as a germicide, and wherein activating a second biological response comprises emitting near infrared light to promote cellular proliferation.

13 . The method of claim 3 , wherein activating a first biological response comprises emitting ultraviolet light to act as a germicide, and wherein activating a second biological response comprises emitting near infrared light to reduce pain.

14 . The method of claim 3 , wherein activating a first biological response comprises photactivating a pharmaceutical agent, and wherein activating a second biological response comprises heating a local area of the target structure.

15 . The method of claim 1 , wherein the predetermined change modifies the target structure or modulates the biological activity of the target structure.

16 . The method of claim 1 , further comprising
contacting the target structure with at least one activatable pharmaceutical agent (PA) that is capable of effecting said predetermined change in the target structure when activated the different wavelengths of light provided internally within the target structure.

17 . The method of claim 1 , wherein said initiation energy generates light that induces the predetermined change in the target structure with or without an energy modulator or a photoactive agent.

18 . The method of claim 1 , further comprising administering to said subject as the one or more light emitters at least one energy modulation agent which adsorbs, intensifies or modifies said initiation energy into an energy that effects the predetermined change in said target structure.

19 . The method of claim 18 , wherein said energy modulation agent comprises at least one of a biocompatible fluorescing metal nanoparticle, fluorescing metal oxide nanoparticle, fluorescing metal coated metal oxide nanoparticle, fluorescing dye molecule, gold nanoparticle, silver nanoparticle, gold-coated silver nanoparticle, a water soluble quantum dot encapsulated by polyamidoamine dendrimers, a luciferase, a biocompatible phosphorescent molecule, a combined electromagnetic energy harvester molecule, and a lanthanide chelate exhibiting intense luminescence.

20 . The method of claim 18 , wherein said energy modulation agent decreases a wavelength of the initiation energy.

21 . The method of claim 20 , wherein said energy modulation agent comprises inorganic materials selected from the group consisting of: metal oxides; metal sulfides; doped metal oxides; and mixed metal chalcogenides.

22 . The method of claim 20 , wherein said energy modulation agent comprises at least one of Y 2 O 3 , Y 2 O 2 S, NaYF 4 , NaYbF 4 , YAG, YAP, Nd 2 O 3 , LaF 3 , LaCl 3 , La 2 O 3 , TiO 2 , LuPO 4 , YVO 4 , YbF 3 , YF 3 , Na-doped YbF 3 , ZnS; ZnSe; MgS; CaS and alkali lead silicate including compositions of SiO 2 , B 2 O 3 , Na 2 O, K 2 O, PbO, MgO, or Ag, and combinations or alloys or layers thereof.

23 . The method of claim 20 , wherein said energy modulation agent comprises at least one of ZnSeS:Cu, Ag, Ce, Tb; CaS: Ce,Sm; La 2 O 2 S:Tb; Y 2 O 2 S:Tb; Gd 2 O 2 S:Pr, Ce, F; LaPO 4 .

24 . The method of claim 20 , wherein said energy modulation agent comprises at least one of ZnS:Ag, ZnS:Cu, Pb, and alloys of the ZnSeS.

25 . The method of claim 20 , wherein said energy modulation agent comprises at least one of sodium yttrium fluoride (NaYF 4 ), lanthanum fluoride (LaF 3 ), lanthanum oxysulfide (La 2 O 2 S), yttrium oxysulfide (Y 2 O 2 S), yttrium fluoride (YF 3 ), yttrium gallate, yttrium aluminum garnet (YAG), gadolinium fluoride (GdF 3 ), barium yttrium fluoride (BaYF 5 , BaY 2 F 8 ), gadolinium oxysulfide (Gd 2 O 2 S), calcium tungstate (CaWO 4 ), yttrium oxide:terbium (Yt 2 O 3 Tb), gadolinium oxysulphide:europium (Gd 2 O 2 S:Eu), lanthanum oxysulphide:europium (La 2 O 2 S:Eu), and gadolinium oxysulphide:promethium, cerium, fluorine (Gd 2 O 2 S:Pr,Ce,F), YPO 4 :Nd, LaPO 4 :Pr, (Ca,Mg)SO 4 :Pb, YBO 3 :Pr, Y 2 SiO 5 :Pr, Y 2 Si 2 O 7 :Pr, SrLi 2 SiO 4 :Pr,Na, and CaLi 2 SiO 4 :Pr.

26 . The method of claim 20 , wherein said energy modulation agent comprises at least one of KSrPO 4 :Eu 2+ , Pr 3+ , NaGdF 4 :Eu, Zn 2 SiO 4 :Tb 3+ , Yb 3+ , β-NaGdF 4 co-doped with Ce 3+ and Tb 3+ ions, and Gd 2 O 2 S:Tm or BaYF 5 :Eu 3+ .

Assignees

• Immunolight Llc

Inventors

• Bourke Jr Frederic A
• Fathi Zakaryae
• Walder Harold

Classifications

• A61N2005/0661

  ultraviolet · CPC title

• A61N5/0624

  for eliminating microbes, germs, bacteria on or in the body · CPC title

• A61N2005/1089

  Electrons · CPC title

• A61N2005/0659

  infrared · CPC title

• A61N5/062 Primary

  Photodynamic therapy, i.e. excitation of an agent · CPC title